// App-Quantinova.ai

: Administration of Rimiducid Following Haploidentical BPX-501 Cells in Children with Malignant or Non-Malignant Disorders Who Develop Graft-Versus-Host-Disease (GvHD)

Researchers

Presenter

  • Reem Elkeky

Principal Investigators

  • David A. Jacobsohn

  • Rajni Agarwal

  • Swati Naik

  • Neena Kapoor

  • Lakshmanan Krishnamurti

  • Mary Slatter

  • Federica Galaverna

  • Pietro Merli

  • Melissa Aldinger

  • Franco Locatelli

Medical Centers

  • Great Ormond Street Hospital, London, United Kingdom

  • Children’S National Med. Ctr., Ctr. For Cancer & Blood Disorders, Washington, DC

  • Stanford Univ, Palo Alto, CA

  • Texas Childrens Hospital, Baylor College of Medicine, Houston, TX

  • Children's Hosp Los Angeles, Los Angeles, CA

  • Department of Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplant, Emory University School of Medicine, Atlanta, GA

  • Great North Children's Hospital, Newcastle, United Kingdom

  • Stem Cell Transplant Unit, Ospedale Bambino Gesu, Rome, Italy

  • Department of Pediatric Hematology/Oncology, IRRCS Ospedale Pediatrico Bambino Gesù, Rome, University of Pavia, Rome, Italy

  • Bellicum Pharmaceutical, Inc., Brisbane, CA

  • Department of Pediatric Hematology and Oncology , IRCCS Ospedale Bambino Gesu, Rome , Italy

Locations

  • United Kingdom

  • United States

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Graft-versus-host disease

Biomarkers

  • N/A

Drug/Treatment

  • Rimiducid

  • BPX-501

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved